Overview


Dr. Stephan Rau focuses his practice on mergers and acquisitions (M&A) transactions and regulatory advice in the health and life science sector. He is the head of the Firm’s Health Law Practice Group in Europe.

Show More

Results


  • Advising on investments in the clinical lab, renal care, hospital, pharma, medical device, biotech, food and online pharmacy businesses
  • Structuring various outsourcing projects, such as joint ventures between one of the largest medical schools in Europe and a large public hospital carrier leading to the establishment of the largest European clinical lab
  • Challenging market entry barriers to dialysis service providers under the German system of determination of need of the statutory health insurance system

Show More

Recognitions


  • Handelsblatt/Best Lawyers™ 2020 Germany: Leading Lawyer for Mergers and Acquisitions Law and Pharmaceuticals Law
  • Leaders League’s 2019 guide, Innovation, Technology & Patents, “Excellent” in the Health, pharma & biotechnology category
  • The Best Lawyers in Germany 2019Mergers & Acquisitions
  • Chambers Europe 2019Leading Individual, Band 1 for Healthcare in Germany
  • Expert Guides; Best of the Best 2018: Regulatory, Financing & Transactional, Germany

Show More

Community


  • German-American Lawyers’ Association
  • German Association of Corporate Law
  • International Bar Association, Health and Life Sciences Law Committee, Co-Chair

Show More

Credentials


Education
Humboldt University of Berlin, Dr. jur. (PhD), 2003
Higher Court of Appeal, Berlin, Second State Exam, 1998
University of Heidelberg, First State Exam, 1996
University of Paris-Dauphine, Maîtrise en Économie Appliquée, 1994
London School of Economics and Political Science, Master of Science in Government, 1993
IHK Wiesbaden, interpreter and translator for Russian, 1990

Show More

Dr. Stephan Rau

Insights & Events / Media

London, United Kingdom / McDermott Event / September 26, 2019

Berlin, Germany / McDermott Event / February 27, 2019

London, United Kingdom / McDermott Event / October 4, 2018

Munich, Germany / McDermott Event / September 25, 2018

Copenhagen, Denmark / McDermott Event / June 13, 2018

Copenhagen, Denmark / Speaking Engagements / June 12, 2018

Copenhagen, Denmark / Speaking Engagements / June 11, 2018

Shanghai, China / McDermott Event / November 16, 2017

Munich, Germany / McDermott Event / September 19, 2017

London, United Kingdom / McDermott Event / June 28, 2017

San Francisco, California / McDermott Event / January 10, 2017

UnternehmerEdition "Health“, Issue 4 / October 2015

Telemedicine in Germany - What Legal Changes Are Needed and What Are ...

PharmaRecht, Issue 4 / April 30, 2015

Comparable Drugs in Price Negotiations Under Sec. 130b SGB V

Pharmind, Issue 11 / November 2014

New Developments On Combating Corruption and Compliance In Healthcare

International Law Office Newsletter, Germany / October 29, 2014

German Perspective on New EU Clinical Trials Regulation

Tokyo, Japan / Diversity Event / October 22, 2014

Munich, Germany / Diversity Event / September 24, 2014

International Law Office Newsletter, Germany / June 18, 2014

Pricing for New Innovative Drugs – Public Payers Attempt New Approach

VC Magazine / April 23, 2014

Legal Framework for Health Apps

International Law Office Newsletter, Germany / February 26, 2014

Generic Drug and API Producers Deal with the Bolar Exemption

International Law Office Newsletter, Germany / February 19, 2014

Yet another Health Reform and Seizure of Retiring Doctors' Practices

Healthcare Marketing - Das Fachmagazin für Gesundheitsmarken, Issue 1-2 / January 2014

Patent Expirations: Generic Drugs and Active Ingredient Producers from the Perspective of ...

1

2

3

4

5